Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
BioTelemetry, Inc. (BEAT - Free Report) : This fashion and lifestyle products retailer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25% over the last 60 days.
BioTelemetry, Inc. Price and Consensus
BioTelemetry’s shares gained 5.2% over the last one month more than S&P 500’s gain of 12.7%. The company possesses a Momentum Score of B.
BioTelemetry, Inc. Price
ABIOMED, Inc. : This developer and seller of medical devices has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.2% over the last 60 days.
ABIOMED, Inc. Price and Consensus
ABIOMED’s shares gained 9.3% over the last one month. The company possesses a Momentum Score of A.
ABIOMED, Inc. Price
AC Immune SA (ACIU - Free Report) : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 50.6% over the last 60 days.
AC Immune SA Price and Consensus
AC Immune’s shares gained 12.7% over the last one month. The company possesses a Momentum Score of B.
AC Immune SA Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
BioTelemetry, Inc. (BEAT - Free Report) : This fashion and lifestyle products retailer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25% over the last 60 days.
BioTelemetry, Inc. Price and Consensus
BioTelemetry’s shares gained 5.2% over the last one month more than S&P 500’s gain of 12.7%. The company possesses a Momentum Score of B.
BioTelemetry, Inc. Price
ABIOMED, Inc. : This developer and seller of medical devices has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.2% over the last 60 days.
ABIOMED, Inc. Price and Consensus
ABIOMED’s shares gained 9.3% over the last one month. The company possesses a Momentum Score of A.
ABIOMED, Inc. Price
AC Immune SA (ACIU - Free Report) : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 50.6% over the last 60 days.
AC Immune SA Price and Consensus
AC Immune’s shares gained 12.7% over the last one month. The company possesses a Momentum Score of B.
AC Immune SA Price
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BEAT - FREE
Get the latest research report on ACIU - FREE